Europium activated bismuth containing double perovskite catalyzed synthesis of coumarin derivatives and its cytotoxicity evaluation

Using NaBaBi_1−xEu_xMoO₆:Eu³⁺(x = 0.0–0.24) europium activated bismuth containing double perovskite materials, a novel heterogeneous catalytic procedure was developed to prepare coumarin and its modified coumarins. Double perovskite catalyst predicts great activity toward a wide range of phenols with variety of that have been substituted with ketoesters in precise yields over short response times during the production of coumarin. Standard protocols were used to prepare various coumarin derivatives, characterized by spectral techniques and eventually evaluated against COLO205, A549, THP-1, B16 and U937 human cancer cells. Compared to the standard drug Etoposide, hybrid 3f demonstrated a higher affinity and better binding interactions with the above cancer cells. UV-fluorescence spectra were recorded for selected coumarin derivatives. However, it is stated here that these molecular hybrids of coumarin could serve as a great starting point for future research to create effective anticancer agents.